NHTC · Natural Health Trends Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.21M | - | $9.48M | $9.81M | $10.74M | - | $10.69M | $10.47M | $10.95M | - |
| Cost of Revenue | $2.30M | - | $2.49M | $2.56M | $2.83M | - | $2.77M | $2.70M | $2.91M | - |
| Gross Profit | $6.90M | - | $6.99M | $7.25M | $7.91M | - | $7.93M | $7.78M | $8.04M | - |
| R&D | - | - | - | - | - | - | - | - | - | - |
| SG&A | $3.52M | - | $3.61M | $3.58M | $3.76M | - | $3.87M | $3.81M | $3.92M | - |
| Total Operating Expenses | $7.38M | - | $7.48M | $7.59M | $8.25M | - | $8.20M | $8.01M | $8.40M | - |
| D&A | $11.0K | - | - | - | $30.0K | - | - | - | $35.0K | - |
| Operating Income | ($474.0K) | - | ($495.0K) | ($333.0K) | ($345.0K) | - | ($275.0K) | ($238.0K) | ($365.0K) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | ($25.0K) | - | $142.0K | $0 | ($2.0K) | - | $131.0K | $108.0K | $10.0K | - |
| Net Income | ($154.0K) | - | ($431.0K) | $15.0K | $122.0K | - | $35.0K | $173.0K | $188.0K | - |
| EPS - Basic | ($0.02) | - | ($0.04) | $0.00 | $0.01 | - | $0.00 | $0.02 | $0.02 | - |
| EPS - Diluted | ($0.02) | - | ($0.04) | $0.00 | $0.01 | - | $0.00 | $0.02 | $0.02 | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $9.22M | $6.81M | $14.34M | $10.53M | $21.69M | $13.53M | $22.90M | $15.58M | $25.82M | $56.18M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | $1.97M | $2.05M | $2.15M | $2.77M | $2.81M | $3.27M | $3.68M | $4.25M | $4.90M | $4.29M |
| Accounts Payable | $1.31M | $555.0K | $1.01M | $962.0K | $968.0K | $895.0K | $548.0K | $653.0K | $749.0K | $990.0K |
| Current Assets | $26.54M | $34.19M | $37.89M | $40.86M | $48.81M | $50.98M | $53.84M | $56.90M | $62.73M | $64.23M |
| Total Assets | $31.95M | $38.43M | $42.25M | $45.16M | $53.18M | $55.36M | $58.29M | $61.49M | $67.64M | $69.09M |
| Current Liabilities | $13.24M | $13.69M | $14.76M | $14.95M | $20.74M | $20.80M | $21.11M | $22.13M | $20.86M | $19.98M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $15.49M | $15.00M | $16.10M | $16.31M | $22.30M | $22.49M | $22.99M | $24.24M | $28.27M | $27.49M |
| Stockholders' Equity | $16.46M | $23.43M | $26.15M | $28.86M | $30.88M | $32.87M | $35.30M | $37.25M | $39.37M | $41.60M |
| Retained Earnings | ($37.45M) | ($36.44M) | ($33.55M) | ($30.81M) | ($28.52M) | ($26.34M) | ($24.22M) | ($21.95M) | ($19.82M) | ($17.70M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($797.0K) | - | - | - | $484.0K | - | - | - | $549.0K | - |
| Investing Cash Flow | $9.94M | - | - | - | $9.97M | - | - | - | ($28.52M) | - |
| Financing Cash Flow | ($6.73M) | - | - | - | ($2.30M) | - | - | - | ($2.30M) | - |
| CapEx | $115.0K | - | - | - | $16.0K | - | - | - | $11.0K | - |
| Free Cash Flow | ($912.0K) | - | - | - | $468.0K | - | - | - | $538.0K | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 75.0% | - | 73.7% | 73.9% | 73.6% | - | 74.1% | 74.2% | 73.4% | - |
| Operating margin | -5.1% | - | -5.2% | -3.4% | -3.2% | - | -2.6% | -2.3% | -3.3% | - |
| EBITDA margin | -5.0% | - | - | - | -2.9% | - | - | - | -3.0% | - |
| Net margin | -1.7% | - | -4.5% | 0.2% | 1.1% | - | 0.3% | 1.7% | 1.7% | - |
| Free cash flow margin | -9.9% | - | - | - | 4.4% | - | - | - | 4.9% | - |
| FCF / Net income | 5.92 | - | - | - | 3.84 | - | - | - | 2.86 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 38.3% | - | 38.1% | 36.4% | 35.0% | - | 36.2% | 36.4% | 35.8% | - |
| Effective tax rate | - | - | - | 0.0% | -1.7% | - | 78.9% | 38.4% | 5.1% | - |
| Return on assets | -0.5% | - | -1.0% | 0.0% | 0.2% | - | 0.1% | 0.3% | 0.3% | - |
| Return on equity | -0.9% | - | -1.6% | 0.1% | 0.4% | - | 0.1% | 0.5% | 0.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.00 | 2.50 | 2.57 | 2.73 | 2.35 | 2.45 | 2.55 | 2.57 | 3.01 | 3.21 |
| Quick ratio | 1.85 | 2.35 | 2.42 | 2.55 | 2.22 | 2.29 | 2.38 | 2.38 | 2.77 | 3.00 |
| Cash ratio | 0.70 | 0.50 | 0.97 | 0.70 | 1.05 | 0.65 | 1.08 | 0.70 | 1.24 | 2.81 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.94 | 1.64 | 1.62 | 1.57 | 1.72 | 1.68 | 1.65 | 1.65 | 1.72 | 1.66 |
| Liabilities / Assets | 0.48 | 0.39 | 0.38 | 0.36 | 0.42 | 0.41 | 0.39 | 0.39 | 0.42 | 0.40 |
| Efficiency | ||||||||||
| Asset turnover | 0.29 | - | 0.22 | 0.22 | 0.20 | - | 0.18 | 0.17 | 0.16 | - |
| Inventory turnover | 1.17 | - | 1.16 | 0.92 | 1.01 | - | 0.75 | 0.64 | 0.59 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 312d | - | 316d | 395d | 363d | - | 486d | 575d | 614d | - |
| Days payable outstanding | 207d | - | 148d | 137d | 125d | - | 72d | 88d | 94d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -14.3% | - | -11.4% | -6.3% | -2.0% | - | 0.7% | -0.3% | -7.7% | - |
| Revenue CAGR (3y) | -8.1% | - | -6.8% | -9.8% | -2.4% | - | -9.2% | -13.4% | -6.7% | - |
| Revenue CAGR (5y) | -7.3% | - | -7.7% | -9.8% | -6.4% | - | -8.9% | -27.1% | -26.9% | - |
| Gross profit growth (YoY) | -12.7% | - | -11.8% | -6.7% | -1.7% | - | 0.0% | -0.9% | -9.0% | - |
| Operating income growth (YoY) | -37.4% | - | -80.0% | -39.9% | 5.5% | - | 5.8% | 68.0% | 7.4% | - |
| Net income growth (YoY) | - | - | - | -91.3% | -35.1% | - | -79.7% | - | -26.8% | - |
| EPS growth (YoY) | - | - | - | - | -50.0% | - | - | - | 0.0% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | 0.0% | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | -12.9% | - | - |
| FCF growth (YoY) | - | - | - | - | -13.0% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -46.7% | -28.7% | -25.9% | -22.5% | -21.6% | -21.0% | -18.5% | -18.0% | -18.1% | -17.1% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$39.78M totalPrimary Reporting Segment$38.39M · 96.5%
China Segment$946.0K · 2.4%
Russia And Kazakhstan Segment$444.0K · 1.1%
Product / service
$40.10M totalProduct$39.02M · 97.3%
Administrative Fees Freight And Other$1.08M · 2.7%
Geographic
$39.78M totalHK$32.67M · 82.1%
TW$1.54M · 3.9%
Peru And Colombia$1.21M · 3.0%
US$1.15M · 2.9%
CN$946.0K · 2.4%
Europe$530.0K · 1.3%
Other Foreign Countries$477.0K · 1.2%
CA$475.0K · 1.2%
Russia And Kazakhstan$444.0K · 1.1%
JP$333.0K · 0.8%
Peer comparison
Same SIC group: Wholesale-Miscellaneous Nondurable Goods
Comparing NATURAL HEALTH TRENDS CORP against the 4 most active filers in the same SIC group.